Background: The treatment of knee osteoarthritis with hyaluronic acid or corticosteroid injection has been widely used.
T he primary goals of knee osteoarthritis treatment are pain reduction and functional improvement. Treatment modalities include muscle-strengthening exercise, aerobic exercise, neuromuscular education, weight reduction, physical therapies, oral analgesics, bracing, nonsteroidal antiinflammatory drugs (NSAIDs), opioids, intra-articular drug injection, and surgical procedures [1] [2] [3] [4] [5] [6] [7] . The American Academy of Orthopaedic Surgeons (AAOS) guidelines strongly recommend against using hyaluronic acid and are unable to recommend for or against using a corticosteroid injection because the evidence is inconclusive 7 .
Hyaluronic acid products and a corticosteroid are commonly used as intra-articular injection agents 2, 4, 8, 9 . Several studies demonstrated that the use of hyaluronic acid injection was safe and effective for decreasing pain and improving function in patients with knee osteoarthritis [10] [11] [12] . A single-shot, intra-articular hylan G-F 20 (hyaluronic acid) injection has been demonstrated to be safe and effective in relieving pain. It may be more convenient and has less adverse events than a multiple-shot injection 13, 14 . A 2009 systematic review showed that an intra-articular corticosteroid injection was also associated with knee pain reduction 15 .
Although both drugs have been demonstrated to provide better pain control and functional improvement than a placebo 3, 16 , studies of corticosteroid and hyaluronic acid injection in patients with knee osteoarthritis have shown variable results [17] [18] [19] [20] [21] . Importantly, little is known with regard to the efficacy of one treatment compared with the other, and the optimal drug for intra-articular injection is still undetermined. There have been limited well-designed, randomized, double-blind studies comparing these 2 drugs.
The aim of this study was to compare the efficacy of single-shot hylan G-F 20 and triamcinolone acetonide injections for relieving pain and improving function in patients with knee osteoarthritis.
Materials and Methods

O
ur institutional ethics committee approved this study before the first patient enrollment. The study protocol was registered at ClinicalTrials. gov (NCT01874574). All patients provided written informed consent for participation in this trial. This study was designed as a single-center, prospective, double-blind, randomized controlled trial with a planned enrollment of 110 participants with symptomatic knee osteoarthritis. Patients did not receive any compensation for participating in this trial. The investigation was performed at Thammasat University Hospital from May 2012 to November 2013.
Patients with symptomatic knee pain were evaluated and were diagnosed with knee osteoarthritis by clinical and radiographic evaluations at an orthopaedic clinic by the senior author. The inclusion criteria included a diagnosis of symptomatic primary knee osteoarthritis according to the American Rheumatism Association classification criteria for knee osteoarthritis 22 , dissatisfaction with conservative treatment (NSAIDs, oral analgesic drugs, physical therapy, or brace), no lumbar spondylosis with radiculopathy, good cognition, and the ability to understand the study protocol and the agreement to participate. The exclusion criteria were an allergy to any of the medications used in this study, bone-on-bone arthritis appearing on any radiograph, varus or valgus deformity of >5°f rom the mechanical axis of the knee, previous fracture or surgical procedure of the investigational knee, previous intra-articular injection in the ipsilateral knee in the past 6 months, and current infection in the affected limb. 
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Study Interventions and Protocol
One hundred and ten patients met the inclusion criteria and were randomized into 2 groups. The randomization method was computer-generation of random numbers by an independent research assistant. This method created 110 study cards, which were titled as either hyaluronic acid or corticosteroid. Each card was placed in a sealed, opaque envelope. An assisting nurse opened the envelope and then allocated patients into 1 of 2 groups after the eligible patient provided informed consent and agreed to participate. Patients received a single intra-articular injection of either hylan G-F 20 (Synvisc; Genzyme Biosurgery) or triamcinolone acetonide. Patient disposition is indicated in a Consolidated Standards of Reporting Trials (CONSORT) flow diagram (Fig. 1) . The mean age of the patients in the hylan G-F 20 group was 63 years (range, 46 to 77 years), and there were 7 men and 43 women. The mean age of the patients in the triamcinolone acetonide group was 61 years (range, 47 to 81 years), and there were 13 men and 36 women. In the hylan G-F 20 group, a single shot of 6 mL of hylan G-F 20 was injected; in the triamcinolone acetonide group, a solution of 1 mL of 40-mg triamcinolone acetonide and 5 mL of 1% lidocaine hydrochloride with 1:100,000 epinephrine was injected. All procedures were performed in an outpatient clinic. Injections were performed by the senior author, who has experience of >500 cases per year in knee joint injections or aspirations. Patients were in a supine position with the eyes blinded. The knee was flexed approximately 60°and was prepared in a sterile fashion, and 1 mL of 2% lidocaine hydrochloride with 1:80,000 epinephrine was infiltrated into the skin and subcutaneous tissue at the lateral soft spot of the knee joint just inferior to the lower pole of the patella with a 27-gauge needle for patient comfort. A 21-gauge needle (0.8 · 50 mm) was then inserted through the same area into the joint capsule. The accuracy of the injection was assessed by an unobstructed injection of 1 mL of air into the knee joint. If an effusion was present, it was aspirated into a separate syringe. The same needle was left in place and then the syringe prefilled with hylan G-F 20 or the triamcinolone acetonide mixture was injected.
Patients and evaluators were blinded. Patients were blinded by the use of an opaque eye shield as they underwent the injection and did not know to which group they were assigned. All patients were under the same post-injection pain control protocol with a prescription of 35-mg orphenadrine citrate and 500-mg acetaminophen (Pormus; Unison Laboratories) that was to be administered on an as-needed basis every 6 hours. The patients were advised not to take any other medications relevant to the treatment of the knee or arthritis.
Investigators who were not aware of the allocation collected demographic data. All patients had radiographs of the knees that included an anteroposterior standing view, a lateral standing view, and a patellar skyline view. The Kellgren and Lawrence grading scale 23 was used to classify the severity of osteoarthritis by 2 authors. The graders were blinded to treatment group at the time of radiographic evaluation. The primary outcomes were knee pain, functional improvement, and knee range of motion at a 6-month follow-up. Knee pain was measured using a 100-mm visual analog scale (VAS), and knee function was measured using 3 dimensions of the modified Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The WOMAC was modified to be consistent with Thai culture and was validated. The 3 item modifications were changes from putting on socks to putting on pants, taking off socks to taking off pants, and getting in or out of the bath to taking a bath 24 . The VAS questionnaires were assessed at baseline; at days 1, 2, and 3; at weeks 1 and 2; and at months 1, 2, 3, 4, 5, and 6. The modified WOMAC questionnaires were completed at baseline, week 2, and months 1, 2, 3, 4, 5, and 6. Patients came to the clinic for evaluation at week 2, month 3, and month 6. Knee range of motion was measured with a goniometer and was recorded by investigators at baseline, week 2, and months 3 and 6.
The secondary outcome variable was adverse reactions related to the injected drug. Drug-related side effects consisted of injection-site reaction, erythema, swelling, injection-site pain, and pruritus.
Statistical Analysis
Multilevel regression models were used to estimate the difference in VAS pain, modified WOMAC score, and range of motion between groups. Significance was set at p < 0.05. A calculation was performed to determine the sample size needed to provide 80% power to demonstrate a difference of >12 points in the VAS score at the 5% significance level in a 2-sided hypothesis test 25 . The expected standard CONSORT flow diagram of the protocol of this study. TA = triamcinolone acetonide. 
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HYLAN G-F 20 HYALURONIC ACID I N J E C T I O N C O M PA R E D W I T H CORTICOSTEROID I N KNEE O S T E OA RT H R I T I S deviation at week 4 after the injection was approximately 21 points in each group
9 . Fifty patients in each group were required to ensure adequate power to detect a similar between-group difference. This study was then designed to enroll 110 participants at baseline (55 participants per group), anticipating that 10% might drop out. The comparison of outcome data in each group before the injection and 6 months after the injection was performed using a paired t test.
Results
O
ne hundred and ten patients were included and were assigned to 1 of 2 treatment groups consisting of 55 patients each. The two groups were similar in baseline characteristics such as demographic characteristics, radiographic grading, mean VAS, mean modified WOMAC score, and mean knee range of motion (Table I) . At the end of the trial, complete clinical assessments were obtained in 99 patients (50 patients in the hylan G-F 20 group and 49 patients in the triamcinolone acetonide group).
Pain Relief
The triamcinolone acetonide injection group had significantly better overall pain improvement than the hylan G-F 20 group (p = 0.02), especially in the first week after injection (Fig. 2) . The difference between groups for the mean VAS score for pain was approximately 11 points from immediately after injection to 1 week (p < 0.05), and then the mean differences became small and were not significant (p > 0.05), as shown in Table II . Patients in both groups showed significant pain relief after injection (p < 0.0001). The effect was observed early after the injection and lasted up to 6 months. At 6 months, the mean change in VAS scores was approximately 230 points in both groups: 229 points (95% CI, 236.4 to 222.7 points) in the hylan G-F 20 group and 230 points (95% CI, 236.0 to 222.8 points) in the triamcinolone acetonide group (p < 0.0001) (Table III) .
Functional Improvement
The hylan G-F 20 and triamcinolone acetonide groups had a similar overall change in the mean modified WOMAC score (p > 0.05) (Fig. 3) . The triamcinolone acetonide group had better mean functional improvement than the hylan G-F 20 group only at 2 weeks after injection (p = 0.029) (Table II) . At the end of 6 months, the mean modified WOMAC scores had significantly improved (p < 0.0001 for both) from 43 to 21 points (95% CI, 16.7 to 29.2 points) in the hylan G-F 20 group and from 39 to 21 points (95% CI, 11.0 to 24.3 points) in the triamcinolone acetonide group (Table III) .
Active Knee Range of Motion
The mean knee range of motion change was not different between the 2 groups at any time point (p > 0.05) (Fig. 4) . At the 6-month follow-up, patients in both groups 
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had significantly improved active knee joint flexion from baseline (p < 0.0001) (Table III) . Patients treated with hylan G-F 20 improved mean knee flexion by 6°(95% CI, 4°to 8°), and patients treated with triamcinolone acetonide also improved mean knee flexion by 8°(95% CI, 5°to 10°).
Adverse Events
There was no serious systemic adverse event in either group. One patient in the hylan G-F 20 group reported knee pain (a VAS score of 50 points) and swelling at day 2 after injection that were relieved by pain medication. There was no acute local reaction or infection in this trial.
Discussion
A triamcinolone acetonide injection provided similar pain improvement compared with hylan G-F 20, except in the first week after injection. The functional score and knee range of motion were also similar between the groups. At 2 weeks after injection, the triamcinolone acetonide group had a significantly better functional score than the hylan G-F 20 group. Both drugs were associated with relieving pain and improving function and knee range of motion without complications. The effect was recognized from day 1 postinjection and lasted up to 6 months. Triamcinolone acetonide relieved pain better and faster in the first week, after which the effect became similar to that of hylan G-F 20 for a follow-up of up to 6 months.
To our knowledge, the study by Conrozier et al. was the first report to examine the safety and efficacy of an alternative dosing regimen using a single 6-mL injection of hylan G-F 20 for the treatment of knee osteoarthritis. Conrozier et al. concluded that a single 6-mL injection of hylan G-F 20 might be as effective and well tolerated as 3 injections of 2 mL administered 1 week apart 14 . In a multicenter, double-blind, randomized study, a single 6-mL intra-articular injection of hylan G-F 20 was safe and provided significant pain relief compared with a placebo over 26 weeks 13 . A meta-analysis of intra-articular corticosteroid injection showed that knee pain was reduced 1 week after injection and the reduction lasted for 3 to 4 weeks 26 . The short-term benefits of intra-articular corticosteroid injection are well recognized, but long-term benefits and the value of repetitive injections are still debatable 27 . There is a perception that corticosteroids are short-lived in their effect, but the current study has confirmed that the triamcinolone acetonide effect may last up to 6 months.
A previous randomized study comparing 3 doses of hylan G-F 20 and multiple corticosteroid injections showed that there was no difference between the 2 drugs in relieving pain and improving function during a 6-month follow-up 28 . Another clinical trial showed that a corticosteroid controlled pain better in the first 1 to 2 weeks, but hyaluronic acid controlled pain better at 12 and 26 weeks 29 . Meta-analyses revealed that intraarticular injection of hyaluronic acid might have a slower onset and longer effects than a corticosteroid 30, 31 . In this study, the reduction of pain was clearly observed since day 1 after the injection in both groups. We used 5 mL of lidocaine with epinephrine combined with triamcinolone acetonide, which might increase the early pain-relieving effect of triamcinolone acetonide. Early pain relief was also detected after a single shot of 6-mL hylan G-F 20, which might cause filling in the joint capsule because of its high molecular weight and high volume. Patients who took triamcinolone acetonide had better pain reduction in the first week after injection than those who took hylan G-F 20; after that, the pain reduction was similar for the entire 6-month period.
With regard to the functional recovery estimated by modified WOMAC scores and active knee range of motion, our study revealed that triamcinolone acetonide provided better functional improvement than hylan G-F 20 at 2 weeks after injection (p = 0.03), but the 2 drugs were otherwise not statistically distinguishable. The functional score and knee motion significantly improved as early as 2 weeks and the improvement lasted up to 6 months in both groups. Hyaluronic acid injection had been shown to improve the WOMAC function and stiffness scores as early as 1 week 32 . We believe this current study to be the first double-blind, randomized controlled trial comparing a single-shot hyaluronic acid injection with a single-shot corticosteroid. The strengths of this study were as follows. First, it was designed as a double-blind, randomized controlled trial that blinded patients who enrolled in the study. Patient blinding may reduce preferential bias for a more expensive and more promoted drug. The investigator who conducted the outcome data evaluation and collection was also blinded to the drug used. Second, the study was funded by an institutional research grant and not by industry. Third, the study was designed to assess the early pain that patients felt, from day 1, and early functional improvement, from 2 weeks after injection. Fourth, there was a high rate of patient adherence to the protocol until the end of study. In addition, we excluded patients with lumbar spondylosis with radiculopathy, which might have confounded the outcome evaluated.
A limitation of this study was that there was no placebo group because it has been demonstrated that both corticosteroid and hyaluronic acid injections have superior efficacy compared with a placebo injection 2, 3, 26 . Even though one metaanalysis has shown that hyaluronic acid is associated with little benefit and an increased risk of serious adverse events 33 , a more recent study with U.S. Food & Drug Administration-approved hyaluronic acid and saline solution control revealed the efficacy and safety of these drugs 34 . In osteoarthritic knee treatment, a placebo may have a mean effect size up to 0.5 35 , which means that the parameter mean at the end point is 0.5 standard deviation below the mean at baseline. In the current study, the effect size found was >1 standard deviation below the mean at baseline, which supports the effectiveness of both drugs during the 6-month follow-up even though there may also have been some placebo effect or regression to the mean.
A corticosteroid may be more cost-effective because of its lower cost compared with hyaluronic acid. It provided better pain relief and similar functional improvement, but only clinical outcomes were investigated. This study did not investigate the effect of drugs on the cartilage and joint structure. An in vivo basic science study would be necessary to determine whether a corticosteroid or hyaluronic acid would actually improve osteoarthritic cartilage abnormalities. Corticosteroids and hyaluronic acid have had reported adverse events in some studies 3, 36, 37 . The adverse events in our study were minimal because the technique of first injecting air to verify that there was no obstruction may have improved the accuracy of our injections.
In conclusion, clinically, patients who received a triamcinolone acetonide injection had similar pain improvement, functional improvement, and knee range of motion at 6 months compared with patients who received a hylan G-F 20 injection, even though patients in the triamcinolone acetonide group had better pain control in the first week and better knee functional improvement in the second week. Triamcinolone acetonide may be more cost-effective, but we have not investigated its effect on cartilage or joint structure. A study with a placebo arm and a basic science study may further clarify these issues. n
